Skip to main content

Table 2 Absorbed dose [mGy/MBq] for all segmented organs for each patient

From: Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer

Organ

Patient no. 1

Patient no. 2

Patient no. 3

Patient no. 4

Patient no. 5

Patient no. 6

Patient no. 7

Patient no. 8

Patient no. 9

Patient no. 10

Kidneys

1.44E−02

2.66E−01

1.74E−01

2.15E−01

1.34E−01

1.29E−01

2.90E−01

7.45E−02

1.72E−01

1.58E−01

Lungs

9.84E−03

1.07E−02

1.24E−02

1.46E−02

9.92E−03

1.19E−02

6.61E−03

9.95E−03

1.19E−02

1.26E−02

Liver

6.40E−02

9.22E−02

8.30E−02

4.22E−02

7.25E−02

9.94E−02

5.95E−02

7.68E−02

7.13E−02

1.00E−01

Spleen

3.04E−02

1.67E−02

1.86E−02

6.92E−03

1.08E−02

1.31E−02

2.12E−02

1.47E−02

2.38E−02

3.27E−02

Salivary glands

6.57E−02

4.13E−02

7.97E−02

4.87E−02

3.12E−02

4.16E−02

3.53E−02

4.82E−02

3.84E−02

3.74E−02

Effective dose

8.64E−03

1.46E−02

1.19E−02

1.08E−02

8.85E−03

1.16E−02

1.30E−02

6.61E−03

1.02E−02

1.26E−02